Use of hormones in the menopausal transition period in the Netherlands between 1993 and 1997

Maturitas

Volumn 53, Issue 4, 2006, Pages 462-475

  Van Duijnhoven, Fränzel J B ^a   Van Gils, Carla H ^a   Bezemer, Irene D ^a   Peeters, Petra H M ^a   Van Der Schouw, Yvonne T ^a   Grobbee, Diederick E ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Hormone therapy; Indicators; Prevalence

Indexed keywords

CONJUGATED ESTROGEN; DESOGESTREL; ESTRADIOL; ESTRADIOL PLUS LEVONORGESTREL; ESTRIOL; ESTROGEN; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; GESTODENE; MEDROXYPROGESTERONE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; TIBOLONE;

ADULT; AGED; ARTICLE; CLIMACTERIUM; CONTROLLED STUDY; DEMOGRAPHY; ESTROGEN THERAPY; FEMALE; HORMONAL THERAPY; HUMAN; HYSTERECTOMY; LIFESTYLE; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MENOPAUSE; NETHERLANDS; ORAL CONTRACEPTION; PATIENT INFORMATION; POPULATION RESEARCH; PUBLIC HEALTH;

AGED; CONFIDENCE INTERVALS; CROSS-SECTIONAL STUDIES; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; HYSTERECTOMY; LINEAR MODELS; MENOPAUSE, PREMATURE; MIDDLE AGED; NETHERLANDS; ODDS RATIO; PERIMENOPAUSE; QUESTIONNAIRES;

EID: 33644616306     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2005.08.002     Document Type: Article

References (54)

1. E. Barrett-Connor Hormone replacement therapy BMJ 317 1998 457 461
2. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer Lancet 350 1997 1047 1059
3. J.E. Rossouw, G.L. Anderson, and R.L. Prentice Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial JAMA 288 2002 321 333
4. R.T. Chlebowski, S.L. Hendrix, and R.D. Langer Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial JAMA 289 2003 3243 3253
5. E. Barrett-Connor The menopause, hormone replacement, and cardiovascular disease: the epidemiologic evidence Maturitas 23 1996 227 234
6. G.L. Anderson, M. Limacher, and A.R. Assaf Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial JAMA 291 2004 1701 1712
7. S. Hulley, D. Grady, and T. Bush Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women Heart and Estrogen/progestin Replacement Study (HERS) Research Group JAMA 280 1998 605 613
8. J.E. Manson, J. Hsia, and K.C. Johnson Estrogen plus progestin and the risk of coronary heart disease N Engl J Med 349 2003 523 534
9. V. Lundberg, H. Tolonen, B. Stegmayr, K. Kuulasmaa, and K. Asplund Use of oral contraceptives and hormone replacement therapy in the WHO MONICA project Maturitas 48 2004 39 49
10. J.E. Mueller, A. Doring, M. Heier, and H. Lowel Prevalence and determinants of hormone replacement therapy in German women Maturitas 43 2002 95 104
11. C. Olesen, F.H. Steffensen, H.T. Sorensen, G.L. Nielsen, J. Olsen, and U. Bergman Low use of long-term hormone replacement therapy in Denmark Br J Clin Pharmacol 47 1999 323 328
12. V. Beral Breast cancer and hormone-replacement therapy in the Million Women Study Lancet 362 2003 419 427
13. D. Grady, T. Gebretsadik, K. Kerlikowske, V. Ernster, and D. Petitti Hormone replacement therapy and endometrial cancer risk: a meta-analysis Obstet Gynecol 85 1995 304 313
14. J.D. Woodruff, and J.H. Pickar Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. The Menopause Study Group Am J Obstet Gynecol 170 1994 1213 1223
15. H.L. Olsson, C. Ingvar, and A. Bladstrom Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden Cancer 97 2003 1387 1392
16. A. Gompel, M. Chaouat, D. Jacob, J.Y. Perrot, H.J. Kloosterboer, and W. Rostene In vitro studies of tibolone in breast cells Fertil Steril 78 2002 351 359
17. Post-menopausal oestrogen therapy IARC Monogr Eval Carcinog Risks Hum 72 1999 399 530
18. Post-menopausal oestrogen-progestogen therapy IARC Monogr Eval Carcinog Risks Hum 72 1999 531 628
19. C. Campagnoli, F. Clavel-Chapelon, R. Kaaks, C. Peris, and F. Berrino Progestins and progesterone in hormone replacement therapy and the risk of breast cancer J Steroid Biochem Mol Biol 96 2005 95 108
20. Y.T. van der Schouw, and D.E. Grobbee Menopausal complaints, oestrogens, and heart disease risk: an explanation for discrepant findings on the benefits of post-menopausal hormone therapy Eur Heart J 26 2005 1358 1361
21. M. Leal, J. Diaz, E. Serrano, J. Abellan, and L.F. Carbonell Hormone replacement therapy for oxidative stress in postmenopausal women with hot flushes Obstet Gynecol 95 2000 804 809
22. T. Naessen, I. Persson, S. Ljunghall, and R. Bergstrom Women with climacteric symptoms: a target group for prevention of rapid bone loss and osteoporosis Osteoporos Int 2 1992 225 231
23. F. Chiaffarino, F. Parazzini, and C. La Vecchia Correlates of hormone replacement therapy use in Italian women, 1992-1996 Maturitas 33 1999 107 115
24. Million Women Study Collaborators Patterns of use of hormone replacement therapy in one million women in Britain, 1996-2000 BJOG 109 2002 1319 1330
25. L.K. Boker, P.A. van Noord, and Y.T. van der Schouw Prospect-EPIC Utrecht: study design and characteristics of the cohort population European Prospective Investigation into Cancer and Nutrition Eur J Epidemiol 17 2001 1047 1053
26. E. Riboli, and R. Kaaks The EPIC Project: rationale and study design European Prospective Investigation into Cancer and Nutrition Int J Epidemiol 26 1997 S6 S14
27. M.C. Ocke, H.B. Bueno-de-Mesquita, and H.E. Goddijn The Dutch EPIC food frequency questionnaire. I. Description of the questionnaire, and relative validity and reproducibility for food groups Int J Epidemiol 26 1997 S37 S48
28. M.C. Ocke, H.B. Bueno-de-Mesquita, M.A. Pols, H.A. Smit, W.A. Van Staveren, and D. Kromhout The Dutch EPIC food frequency questionnaire II. Relative validity and reproducibility for nutrients Int J Epidemiol 26 1997 S49 S58
29. L.E. Voorrips, A.C. Ravelli, P.C. Dongelmans, P. Deurenberg, and W.A. Van Staveren A physical activity questionnaire for the elderly Med Sci Sports Exerc 23 1991 974 979
30. S.M. McKinlay The normal menopause transition: an overview Maturitas 23 1996 137 145
31. R. Hardy, D. Kuh, and M. Wadsworth Smoking, body mass index, socioeconomic status and the menopausal transition in a British national cohort Int J Epidemiol 29 2000 845 851
32. H. Tobi, P.B. van den Berg, J.R. Brouwers, and L.T. de Jong-van den Berg Hormone replacement therapy in the peri-menopausal and post menopausal period: more than half of the women were treated for more than one year Ned Tijdschr Geneeskd 147 2003 1853 1855
33. F.P. Groeneveld, F.P. Bareman, R. Barentsen, H.J. Dokter, A.C. Drogendijk, and A.W. Hoes Duration of hormonal replacement therapy in general practice; a follow-up study Maturitas 29 1998 125 131
34. H.J. Coelingh Bennink Are all estrogens the same? Maturitas 47 2004 269 275
35. Breast cancer and hormonal contraceptives. Collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies Collaborative Group on Hormonal Factors in Breast Cancer Lancet 347 1996 1713 1727
36. Y.S. Khader, J. Rice, L. John, and O. Abueita Oral contraceptives use and the risk of myocardial infarction: a meta-analysis Contraception 68 2003 11 17
37. J.M. Kemmeren, A. Algra, and D.E. Grobbee Third generation oral contraceptives and risk of venous thrombosis: meta-analysis BMJ 323 2001 131 134
38. T.M. Farley, J. Collins, and J.J. Schlesselman Hormonal contraception and risk of cardiovascular disease. An international perspective Contraception 57 1998 211 230
39. B. de Lignieres, F. de Vathaire, and S. Fournier Combined hormone replacement therapy and risk of breast cancer in a French cohort study of 3175 women Climacteric 5 2002 332 340
40. A. Fournier, F. Berrino, E. Riboli, V. Avenel, and Clavel-Chapelon F Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort Int J Cancer 114 3 2005 448 454
41. L. Manzoli, P. Di Giovanni, and L. Del Duca Use of hormone replacement therapy in Italian women aged 50-70 years Maturitas 49 2004 241 251
42. K. Rodstrom, C. Bengtsson, L. Lissner, and C. Bjorkelund Pre-existing risk factor profiles in users and non-users of hormone replacement therapy: prospective cohort study in Gothenburg Sweden BMJ 319 1999 890 893
43. K. Bakken, A.E. Eggen, and E. Lund Hormone replacement therapy in Norwegian women, 1996-1997 Maturitas 40 2001 131 141
44. K.A. Matthews, L.H. Kuller, R.R. Wing, E.N. Meilahn, and P. Plantinga Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am J Epidemiol 143 1996 971 978
45. N.L. Keating, P.D. Cleary, A.S. Rossi, A.M. Zaslavsky, and J.Z. Ayanian Use of hormone replacement therapy by postmenopausal women in the United States Ann Intern Med 130 1999 545 553
46. K.M. Brett, and C.A. Reuben Prevalence of estrogen or estrogen-progestin hormone therapy use Obstet Gynecol 102 2003 1240 1249
47. A.S. Midgette, and J.A. Baron Cigarette smoking and the risk of natural menopause Epidemiology 1 1990 474 480
48. B. MacMahon, D. Trichopoulos, P. Cole, and J. Brown Cigarette smoking and urinary estrogens N Engl J Med 307 1982 1062 1065
49. N.C. Onland-Moret, P.H. Peeters, Y.T. van der Schouw, D.E. Grobbee, and C.H. van Gils Alcohol and endogenous sex steroid levels in postmenopausal women: a cross-sectional study J Clin Endocrinol Metab 90 2005 1414 1419
50. J.S. Gavaler, K. Love, and D. Van Thiel An international study of the relationship between alcohol consumption and postmenopausal estradiol levels Alcohol Alcohol Suppl 1 1991 327 330
51. J.S. Gavaler, and D.H. Van Thiel The association between moderate alcoholic beverage consumption and serum estradiol and testosterone levels in normal postmenopausal women: relationship to the literature Alcohol Clin Exp Res 16 1992 87 92
52. P.K. Verkasalo, H.V. Thomas, P.N. Appleby, G.K. Davey, and T.J. Key Circulating levels of sex hormones and their relation to risk factors for breast cancer: a cross-sectional study in 1092 pre- and postmenopausal women (United Kingdom) Cancer Causes Control 12 2001 47 59
53. F.P. Groeneveld, F.P. Bareman, R. Barentsen, H.J. Dokter, A.C. Drogendijk, and A.W. Hoes Determinants of first prescription of hormone replacement therapy. A follow-up study among 1689 women aged 45-60 years Maturitas 20 1994 81 89
54. N. Schmitt, J. Gogate, and M. Rothert Capturing and clustering women's judgment policies: the case of hormonal therapy for menopause J Gerontol 46 1991 92 101